Kite Pharma (KITE) has been under a strong bear grip, hence the stock is down -4.42% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.19% in the past 1 week. The stock has risen by 2.36% in the past week indicating that the buyers are active at lower levels, but the stock is down -4.94% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 2.08% and the 50-Day Moving Average is 2.68%.The 200 Day SMA reached 7.76%
Kite Pharma (NASDAQ:KITE): The stock opened in the green at $56.09 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $57.394 and a low of $55.2 for the day. The stock did not find buyers even at the lows and closed at $55.86 recording a loss of -0.21%. 1,425,909 shares exchanged hands during the trading day. The stock had closed at $55.86 in the previous days trading.
Kite Pharma (KITE) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $80 and the lowest price target forecast is $61. The average forecast of all the analysts is $73.38 and the expected standard deviation is $7.05.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Companys lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.